Artivion, Inc. Form 4 Filings

ARTIVION, INC. (AORT) reported that Andrew M. Green, its SVP, Regulatory and Quality, sold a total of 8,003 shares of common stock in two open-market transactions. On September 2, 2026 he sold 6,510 shares at a weighted average price of $27.265, and on September 3, 2026 he sold 1,493 shares at a weighted average price of $26.016. The price figures are footnoted as weighted averages over ranges of individual sale prices, and no Rule 10b5-1 trading plan is reported.

ARTIVION, INC. (AORT) reported that President & CEO James P. Mackin sold 70,000 shares of common stock on 2026-08-19 in an open market or private transaction. The shares were sold at a weighted average price of $28.955 per share, with individual sale prices ranging from $28.89 to $29.15. Following this transaction, Mackin directly holds 877,275 shares of ARTIVION common stock. The transaction was not marked as made under a Rule 10b5-1 trading plan.

ARTIVION, INC. executive Andrew M. Green, SVP, Regulatory and Quality, reported a sale of 616 shares of common stock on 2026-08-14 at $28.549 per share. According to the company’s disclosure, these shares were sold in a “sell to cover” transaction solely to satisfy tax withholding obligations upon vesting of restricted stock units and did not represent a discretionary trade. Following this transaction, Green directly holds 59,643 shares of ARTIVION common stock.

Artivion, Inc. (AORT) reported that executive officer Lance A. Berry, EVP, COO, CFO & Treasurer, had 715 shares of common stock sold on his behalf on 2026-08-14 at $28.549 per share. According to the company, this was a non-discretionary “sell to cover” transaction to satisfy tax withholding obligations upon vesting of restricted stock units, and Berry’s directly held stake after the sale was 210,112 shares.

Jean F. Holloway, SVP and General Counsel of Artivion, Inc., reported a sale of 977 shares of Artivion common stock on 2026-08-12 in a transaction categorized as a "Sale in open market or private transaction" at a price of $28.49 per share. Following this sale, Holloway directly holds 184,118 shares of Artivion common stock. The filing’s Rule 10b5-1 checkbox is unchecked, and a footnote states that the reported price reflects the price at which the shares were sold.

ARTIVION, INC. senior vice president Andrew M. Green reported an exercise-and-sell transaction in company stock. He exercised stock options for a total of 44,001 shares of common stock at exercise prices of $11.03 and $18.44 per share, then sold the same 44,001 shares in open-market transactions at weighted average prices of $20.694 and $20.707 per share. These trades were carried out on June 11, 2026 under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, Green continued to hold 60,259 shares of Artivion common stock directly.

ARTIVION, INC. director Anthony B. Semedo reported an internal restructuring of his holdings with no sale for value. On June 2, 2026, 6,325 shares of common stock were transferred from his directly held account to the Stacie Nelson and Anthony Semedo Living Trust for estate planning purposes.

After the transfer, he held 40,635 shares directly and 6,325 shares indirectly through the revocable living trust, which he and his spouse administer and may be deemed to beneficially own. An additional 600 shares were held indirectly through his spouse. These changes reflect only a shift in the form of ownership.

Borgstrom Marna P reported acquisition or exercise transactions in this Form 4 filing.

ARTIVION, INC. director Marna P. Borgstrom corrected a previously reported equity grant on an amended insider filing. The filing confirms a restricted stock award of 7,576 common shares granted on May 18, 2026, at no cost, which will vest on May 18, 2027, under the company’s Equity and Cash Incentive Plan.

After this correction, Borgstrom is shown as beneficially owning 56,664 common shares directly. The amendment states these changes fix administrative errors in the original Form 4 regarding the grant date, share amount, vesting date, and reported total holdings, with no other changes made.

SEMEDO ANTHONY B. reported acquisition or exercise transactions in this Form 4 filing.

ARTIVION, INC. director Anthony B. Semedo received a grant of 7,576 shares of common stock as a stock award, with no cash paid per share. This award is scheduled to vest on May 18, 2027 under the company’s Equity and Cash Incentive Plan.

After this grant, Semedo directly holds 46,960 shares of ARTIVION common stock and also indirectly owns 600 shares through his spouse, giving investors a clearer view of his equity-based compensation and overall stake in the company.

Salveson Jon W reported acquisition or exercise transactions in this Form 4 filing.

ARTIVION, INC. director Jon W. Salveson reported receiving a grant of 7,576 shares of common stock as a stock award. The shares were granted at no cash cost to him and are scheduled to vest on May 18, 2027 under the company’s Equity and Cash Incentive Plan. After this award, his direct holdings increased to 137,416 shares of Artivion common stock.

Hoff Elizabeth A reported acquisition or exercise transactions in this Form 4 filing.

ARTIVION, INC. director Elizabeth A. Hoff reported receiving a grant of 7,576 shares of common stock as equity compensation. The shares were awarded at no cash cost per share and increased her directly held position to 34,765 shares. According to the footnote, this restricted stock award is scheduled to vest on May 18, 2027 under the company’s Equity and Cash Incentive Plan, meaning she will fully earn the shares over time if vesting conditions are met.

Burbank Jeffrey H reported acquisition or exercise transactions in this Form 4 filing.

ARTIVION, INC. director Jeffrey H. Burbank received a grant of 7,576 shares of Common Stock on May 18, 2026, at no purchase price. The RSA grant is scheduled to vest on May 18, 2027, under the company’s Equity and Cash Incentive Plan. Following this award, he directly holds 61,372 shares of Artivion stock.

Bullock James reported acquisition or exercise transactions in this Form 4 filing.

ARTIVION, INC. director James Bullock reported receiving a grant of 7,576 shares of Common Stock as equity compensation. The award carried a price of $0.00 per share and increased his directly held stake to 76,223 shares. According to the disclosure, this restricted stock award vests on May 18, 2027 under the company’s Equity and Cash Incentive Plan, indicating it is a time-based compensation grant rather than an open-market purchase.

BEVEVINO DANIEL J reported acquisition or exercise transactions in this Form 4 filing.

ARTIVION, INC. director Daniel J. Bevevino reported receiving a grant of 7,576 shares of common stock as equity compensation. The award carried a price of $0.00 per share and increased his directly held position to 157,637 shares after the transaction. According to the footnote, this RSA grant will vest on May 18, 2027 under the company’s Equity and Cash Incentive Plan.

ARTIVION, INC. director Thomas F. Ackerman received an equity grant of 7,576 shares of common stock on May 18, 2026, at no cash cost, classified as a grant, award, or other acquisition under the company’s plan. These restricted shares vest on May 18, 2027, pursuant to the Equity and Cash Incentive Plan. Following this award, Ackerman directly holds 157,472 shares of Artivion common stock.

Borgstrom Marna P reported acquisition or exercise transactions in this Form 4 filing.

ARTIVION, INC. director Marna P. Borgstrom reported an equity compensation grant of 7,850 shares of Common Stock. The award was received at a stated price of $0.00 per share and is part of the company’s Equity and Cash Incentive Plan.

After this grant, Borgstrom directly holds 56,938 shares of Artivion common stock. According to the footnote, the RSA grant is scheduled to vest on May 14, 2027, aligning director compensation with the company’s long-term performance.

ARTIVION, INC. VP and Chief Accounting Officer Amy Horton reported both a stock award and a small share sale. She received 7,475 shares of common stock on March 2, 2026 as part of a performance stock unit grant made on February 28, 2025, with additional portions scheduled to vest in 2027 and 2028 if she remains employed on those dates. On March 3, 2026, 901 shares were sold at an average price of $37.7756 to cover tax withholding obligations arising from the vesting of performance stock units, and this "sell to cover" was described as non-discretionary. After the sale, she directly held 139,088 shares of common stock.

ARTIVION, INC. executive Jean F. Holloway, SVP and General Counsel, reported equity compensation activity and related tax sales in company stock. She acquired 27,795 shares of common stock on a grant or award basis at $0.00 per share, tied to performance stock units granted in February 2025, with remaining portions scheduled to vest in February 2027 and February 2028 subject to continued employment. Following this vesting, she sold 3,843 shares at an average price of $37.7756 on March 3, 2026 and 8,962 shares at $38.00 on March 4, 2026 solely to cover tax withholding obligations under a “sell to cover” arrangement, which the filing states is not a discretionary transaction. After these transactions, she directly owned 185,095 shares of Artivion common stock.

ARTIVION, INC. senior vice president Stanton Marshall S. reported two stock transactions involving company common shares. He acquired 21,838 shares on a grant/award basis at $0.0000 per share as part of performance stock units granted in February 2025. According to the award terms, additional portions of this grant are eligible to vest on February 28, 2027 and February 28, 2028, subject to continued employment on each vesting date. On March 3, 2026, 2,149 shares were sold at an average price of $37.7756 per share to cover tax withholding obligations through a sell-to-cover transaction, which the company notes was not a discretionary sale. After these transactions, Marshall directly owned 60,097 shares of Artivion common stock.

Artivion, Inc. Chief Commercial Officer John E. Davis reported two equity transactions in company common stock. On March 2, 2026, he acquired 28,845 shares at $0.00 per share, issued upon vesting of performance stock units from a February 2025 grant. On March 3, 2026, 4,573 shares were sold at an average price of $37.7756 per share to cover tax withholding obligations in a non-discretionary “sell to cover” transaction. Following these movements, Davis held 230,794 shares of Artivion common stock directly.

Artivion, Inc. executive Lance A. Berry reported equity compensation activity and a related tax sale of shares. He acquired 40,874 shares of common stock on a grant or award basis at a price of $0.0000 per share on March 2, 2026, connected to performance stock units granted on February 28, 2025. One third of these units were issued on March 2, 2026, with the remaining thirds scheduled to be eligible to vest on February 28, 2027 and February 28, 2028, assuming continued employment.

On March 3, 2026, 6,316 shares of common stock were sold in an open-market transaction at an average price of $37.7756 per share to cover tax withholding obligations arising from the vesting of these performance stock units. The filing states this “sell to cover” transaction was undertaken to satisfy tax obligations and does not represent a discretionary trade. Following these transactions, Berry directly held 210,827 shares of Artivion common stock.

Artivion, Inc. President & CEO James P. Mackin reported both an equity award and a related share sale. He acquired 116,948 shares of common stock on a grant/award basis at $0.00 per share following the vesting of performance stock units from a February 2025 grant.

On the next trading day, he sold 17,887 shares of common stock at an average price of $37.7756 per share in an open‑market transaction specifically to cover tax withholding obligations under a “sell to cover” arrangement, characterized as a non‑discretionary transaction. Following these transactions, he directly owned 947,275 shares of Artivion common stock.

Artivion, Inc. executive reports tax-related share sale. VP and Chief Accounting Officer Amy Horton disposed of 641 shares of common stock in an open-market transaction at about $38.02 per share. According to the footnote, the shares were sold automatically to cover tax withholding upon restricted stock unit vesting and were not a discretionary trade. After this transaction, she directly holds 132,514 shares.

Artivion, Inc. senior vice president Stanton Marshall S. reported an automatic sale of 1,513 shares of common stock at an average price of $38.0249 per share. According to the filing, the shares were sold upon vesting of restricted stock units solely to cover tax withholding obligations and were not a discretionary trade. After this transaction, he directly holds 40,408 shares of Artivion common stock.

Artivion, Inc. President and CEO James P. Mackin reported an open-market sale of 14,911 shares of common stock at an average price of $38.0249 per share. According to the footnote, the shares were sold solely to cover tax withholding obligations upon the vesting of restricted stock units and did not represent a discretionary transaction. After this sale, Mackin beneficially owned 848,214 shares of Artivion common stock directly.

Artivion, Inc. senior vice president and general counsel Jean F. Holloway reported an automatic sale of company stock related to tax withholding. On this Form 4, she disposed of 2,183 shares of common stock at a weighted average price of $38.0249 per share in an open-market transaction. A footnote explains that the shares were sold upon the vesting of restricted stock units solely to cover tax withholding obligations through a “sell to cover” arrangement and did not represent a discretionary trade. After this transaction, Holloway directly owned 170,105 shares of Artivion common stock.

Artivion, Inc. executive Lance A. Berry reported a tax-related share sale. On this Form 4, the EVP, COO, CFO & Treasurer sold 5,178 shares of common stock at an average price of $38.0249 per share in connection with the vesting of restricted stock units.

The filing explains that the shares were sold solely to satisfy tax withholding obligations through a “sell to cover” arrangement and is described as a non-discretionary transaction rather than an elective open-market sale. After this transaction, Berry directly holds 176,269 shares of Artivion common stock.

ARTIVION, INC. Chief Commercial Officer John E. Davis reported an open-market sale of 2,784 shares of common stock. The shares were sold at an average price of $38.0249 per share in connection with the vesting of restricted stock units to cover tax withholding obligations.

After this sell-to-cover, Davis directly holds 206,522 shares of Artivion common stock. The filing states that this transaction was not discretionary and was executed solely to satisfy required tax withholding on equity compensation.

ARTIVION, INC. executive Amy Horton, VP and Chief Accounting Officer, reported both stock sales and a stock grant. On February 23, 2026, she sold 1,731 shares of common stock at $37.588 per share, and on February 24, 2026, she sold 830 shares at $35.693 per share.

According to the footnotes, both sales were automatic "sell to cover" transactions to pay tax withholding upon vesting of performance and restricted stock units, and did not represent discretionary trades. Horton also received a grant of 5,658 shares of restricted stock at no cost, which vest in three equal annual installments, and held 133,155 shares directly after these transactions.

Artivion, Inc. SVP Stanton Marshall S. reported two open-market sales of common stock that were executed solely to cover tax withholding on vesting equity awards. On February 23, 2026, he sold 2,423 shares at an average price of $37.588 per share. On February 24, 2026, he sold an additional 1,259 shares at an average price of $35.693 per share. The footnotes state these were "sell to cover" transactions to satisfy tax obligations and did not represent discretionary trading decisions. After the latest transaction, he directly owned 41,921 common shares.

Artivion, Inc. senior vice president and general counsel Jean F. Holloway reported both stock sales and an equity award in company shares. On February 23–24, 2026, she sold a total of 4,747 shares of common stock at prices of $37.588 and $35.693 per share.

Footnotes state these sales were automatically executed to cover tax withholding owed upon vesting of performance and restricted stock units, and are not discretionary trades. She also received a grant of 20,085 shares of restricted stock at no cost, which vest in three equal annual installments starting on the first anniversary of the grant date.

ARTIVION, INC. President & CEO James P. Mackin reported both automatic tax-related sales and an equity award of common stock. On February 23–24, he sold a total of 34,898 shares at prices around $35.69–$37.59 in pre-arranged “sell to cover” transactions to pay tax withholding on vesting performance and restricted stock units, which the company notes were not discretionary trades. On February 24, he also received a grant of 97,030 shares of restricted stock at no purchase price, vesting 33 1/3% per year starting on the first anniversary of the grant under the Equity and Cash Incentive Plan. Following these transactions, Mackin directly holds 863,125 shares of Artivion common stock.

Artivion, Inc. executive Lance A. Berry reported routine equity compensation activity. On February 23 and 24, he sold 4,981 and 4,485 shares of common stock at $37.588 and $35.693 per share, respectively, to cover tax withholding triggered by vesting of performance and restricted stock units, which the company notes were non-discretionary “sell to cover” transactions.

On February 24, he also acquired a grant of 37,482 shares of restricted stock at no cost, which vest in equal thirds annually starting on the first anniversary of the grant date under the Equity and Cash Incentive Plan. Following these transactions, his directly held common stock increased to 181,447 shares.

Artivion, Inc.’s Chief Commercial Officer John E. Davis reported a mix of stock compensation activity and related tax sales. He received a grant of 20,438 shares of restricted stock, which vest in equal thirds each year starting on the first anniversary of the grant date.

To cover tax withholding from vesting performance and restricted stock units, 5,848 shares were automatically sold in open-market transactions at prices of about $35.69 and $37.59 per share, described as non-discretionary “sell to cover” sales. After these transactions, Davis directly owns 209,306 shares of common stock.

Artivion, Inc.'s Chief Commercial Officer reported selling company stock in an insider transaction. On 12/15/2025, John E. Davis sold 5,000 shares of Artivion common stock at $45.11 per share, as reflected in a regulatory report.

After this sale, Davis beneficially owned 193,842 Artivion shares, all held directly. The report was filed by him as a single reporting person in his role as Chief Commercial Officer.

Artivion, Inc. insider Form 4 details a routine tax-related stock sale. The company’s Vice President and Chief Accounting Officer reported selling 4,572 shares of Artivion common stock on 12/08/2025 at a price of $44.419 per share. After this transaction, the officer beneficially owned 130,058 shares directly.

The filing explains that the shares were sold automatically upon the vesting of restricted stock units to cover tax withholding obligations through a “sell to cover” transaction, meaning it was not a discretionary open-market trade by the insider.

Artivion, Inc. reported an insider stock transaction by its President & CEO, James P. Mackin. On December 3, 2025, he exercised stock options to acquire 30,921 shares of Artivion common stock at an exercise price of $29.62 per share, then sold the same 30,921 shares in the open market at a weighted average price of approximately $45.461 per share.

The option exercise and sale were conducted under a Rule 10b5-1 trading plan adopted on September 2, 2025. After these transactions, he directly owns 800,993 shares of Artivion common stock. The reported stock option, originally granted on March 5, 2020 with an expiration date of March 5, 2026, is now fully exercised and shows 0 options remaining.

Artivion, Inc. executive Jean F. Holloway, the company’s SVP and General Counsel, reported open-market sales of company stock. On 12/03/2025, she sold 2,048 shares of Artivion common stock at a price of $45.3 per share and, in a separate transaction the same day, sold an additional 5,267 shares at $45.3 per share.

Following these transactions, Holloway beneficially owns 156,093 shares of Artivion common stock directly. The filing is a standard Form 4 disclosure of insider trading activity required for company officers.

Artivion, Inc. (AORT) reported an insider stock transaction by its President & CEO. On 12/02/2025, the executive exercised stock options to buy 30,921 shares of common stock at an exercise price of $29.62 per share and then sold 30,921 shares of common stock in a separate transaction at a weighted average price of $45.559 per share.

The transactions were executed under a Rule 10b5-1 trading plan adopted on September 2, 2025. Following these moves, the reporting person held 800,993 shares of Artivion common stock in direct ownership.

Artivion, Inc. executive reports charitable stock gift

An officer of Artivion, Inc., serving as VP and Chief Accounting Officer, filed a Form 4 reporting a gift of 750 shares of Artivion common stock on 12/01/2025. The transaction is coded as a gift and priced at $0, reflecting that the shares were donated rather than sold. After this transaction, the reporting person directly owns 134,630 shares of Artivion common stock. The explanation clarifies that the 750 shares were gifted to a charity.

Artivion, Inc. (AORT) senior vice president Marshall Stanton reported multiple stock option exercises and related share sales dated 11/21/2025. He exercised options to buy 20,301 shares of common stock at $18.44 per share and another 27,075 shares at $11.03 per share. On the same date, he sold blocks of 14,586 shares at a weighted average price of $44.919, 5,715 shares at $45.346, 18,705 shares at $44.91, and 8,370 shares at $45.345, with each price representing a weighted average within disclosed ranges. After these transactions, he directly owned 44,753 shares of Artivion common stock.

Artivion, Inc. (AORT) senior vice president of Clinical & MD Affairs Marshall Stanton reported insider transactions in company stock. On 11/20/2025, he sold 11,888 shares of common stock at a weighted average price of $44.14 per share, and in separate transactions sold additional shares at weighted average prices of $44.315 and $44.278 per share. The sales were reported as open-market dispositions.

On the same date, Stanton exercised stock options to buy 2,033 shares at an exercise price of $18.44 per share and 1,355 shares at an exercise price of $11.03 per share, then sold the corresponding shares. Following these transactions, he reported beneficial ownership of 44,753 shares of Artivion common stock held directly, along with vested and unexercised stock options covering 20,301 shares at $18.44 and 27,075 shares at $11.03.

Artivion, Inc. (AORT) director share sale disclosed

A director of Artivion, Inc. reported selling 4,200 shares of the company’s common stock on 11/18/2025 at a weighted average price of $45.098 per share, with individual sale prices ranging from $44.89 to $45.295. After this transaction, the director beneficially owns 27,189 shares directly. The price range disclosure indicates multiple trades were executed to complete the total sale.

Artivion, Inc. (AORT) senior vice president and general counsel Jean F. Holloway reported option exercises and related stock sales in November 2025. On November 14, 2025, she exercised options to acquire 6,393 shares of common stock at $29.62 per share and sold 6,393 shares at $45.00 per share, leaving 169,801 shares owned directly, then 163,408 shares after the sale. On November 17, 2025, she exercised options for 6,394 shares at $29.62 and sold 6,394 shares at $45.17, with 169,802 shares shown after the exercise and 163,408 shares directly owned after the sale.

The derivative table shows these transactions came from stock options granted with a $29.62 exercise price and an expiration date of March 5, 2026. The filing notes that the option exercises and subsequent sales were carried out under a Rule 10b5-1 trading plan adopted on August 14, 2025, and that the options vested in equal annual installments beginning March 5, 2020.

Artivion, Inc. (AORT) reported insider share transactions by its Chief Commercial Officer on Form 4. On November 14, 2025 and November 17, 2025, the officer exercised stock options to acquire 6,393 and 6,394 shares of common stock, respectively, at an exercise price of $29.62 per share. On the same dates, the officer sold the same numbers of shares at prices of $44.67 and $45.17 per share. After these transactions, the officer directly owned 198,842 shares of Artivion common stock. The filing notes that the option exercises and related sales were carried out under a Rule 10b5-1 trading plan adopted on August 14, 2025, and that the options originally began vesting on March 5, 2020.

Artivion, Inc. (AORT) reported an insider stock sale by a senior officer. On 11/17/2025, the company’s VP and Chief Accounting Officer sold 6,000 shares of common stock in an open market transaction at a weighted average price of $45.73 per share, with trade prices ranging from $45.605 to $45.91. After this transaction, the officer beneficially owns 135,380 shares of Artivion common stock, held directly. The filing notes that detailed price breakdowns for each trade within the reported range are available upon request.

Artivion (AORT) disclosed an insider transaction by its VP, Chief Accounting Officer. On 11/13/2025, the officer sold 3,482 shares of common stock at $45.858 per share. According to the filing, the sale was executed to cover tax withholding triggered by the vesting of restricted stock units and “does not represent a discretionary transaction.”

Following this sell-to-cover transaction, the officer beneficially owned 141,380 shares, held directly.

Artivion, Inc. (AORT) reported an insider Form 4. The Chief Commercial Officer sold 6,563 shares of common stock at $45.858 on 11/13/2025 (Transaction code: S). According to the footnote, the shares were sold upon RSU vesting to cover tax withholding via a “sell to cover” and do not represent a discretionary transaction.

After the sale, the reporting person beneficially owned 198,842 shares, held directly.

Artivion, Inc. (AORT) President & CEO James P. Mackin reported a Form 4 transaction: the sale of 34,210 shares of common stock at $45.858 on November 13, 2025. The filing states the shares were sold upon RSU vesting to satisfy tax withholding via a “sell to cover” and did not represent a discretionary transaction.

Following the sale, Mackin beneficially owned 800,993 shares, held directly. The transaction code was S, reflecting an open-market or private sale executed to cover withholding obligations tied to equity compensation vesting.